HongKong:HK.02500

Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval

HANGZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced today that, VenusP-Valve, the company's in-house developed innovative transcatheter pulmonic valve replaceme...

2024-02-05 21:00 2089

Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023

The company will be presenting its growing pipeline of superb technologies for treating all four heart valves in its booth and at multiple events during the conference. HANGZHOU, China, Nov. 20, 2023 /PRNewswire/ -- Venus Medtech is changing how the world treats structural heart disease. The com...

2023-11-20 07:09 2049

Confirmatory clinical trial of Liwen RF™ ablation system in China concluded

HANGZHOU, China, March 6, 2023 /PRNewswire/ -- On March 3, Venus Medtech ( Hangzhou) Inc. (Venus Medtech, 2500.HK), trailblazer in structural heart therapies worldwide, announced that the Liwen RF™ ablation system developed by the Company has successfully enrolled one patient at West China Hospita...

2023-03-06 07:29 2639

Venus Medtech to showcase its structural heart treatments at London Valves 2022

The company's growing number of solutions for structural heart disease will be presented at multiple events during the conference betweenNovember 27-29 HANGZHOU, China, Nov. 25, 2022 /PRNewswire/ -- Venus Medtech is building an exciting pipeline of treatments for structural heart disease. The co...

2022-11-25 18:08 7234

Filling gap in market: VenusP-Valve™ approved by China's NMPA

HANGZHOU, China, July 13, 2022 /PRNewswire/ -- On July 11, 2022, VenusP-ValveTM , Venus Medtech's in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, was approved byChina's National Medical Products Administration (NMPA) for the treatment of severe pulmonary regur...

2022-07-13 20:26 2613

First American Patient Treated with VenusP-Valve™ Under Compassionate Use

HANGZHOU, China, June 22, 2022 /PRNewswire/ -- VenusP-Valve™, an in-house developed novel medical device of Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), recently completed its first compassionate use atUniversity of Virginia Advanced Cardiac Valve Center in...

2022-06-22 18:02 2268

Venus Medtech announces 2021 annual results: pacesetter in China and breakthrough-maker worldwide

HANGZHOU, China, April 1, 2022 /PRNewswire/ -- On March 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced its annual results for the yea...

2022-04-01 10:34 2337

Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercialization of TPVR system

HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18th, 2022, Venus Medtech (Hangzhou) Inc. ("Venus Medtech", 2500.HK), a leading provider of integrated solutions for structural heart disease inChina, announced the appointment ofShakeel Osman as Senior Vice President of Sales Europe, resp...

2022-03-18 20:02 4392